Restrictions set on use of hepatitis C drug Maviret

Taiwan's Food and Drug Administration (FDA) has imposed restrictions on the use of an antiviral medicine used to treat patients with chronic (long-term) hepatitis C, an infectious disease that affects the liver.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)